- Conversion of Aldehydes to Branched or Linear Ketones via Regiodivergent Rhodium-Catalyzed Vinyl Bromide Reductive Coupling-Redox Isomerization Mediated by Formate
-
A regiodivergent catalytic method for direct conversion of aldehydes to branched or linear alkyl ketones is described. Rhodium complexes modified by PtBu2Me catalyze formate-mediated aldehyde-vinyl bromide reductive coupling-redox isomerization to form branched ketones. Use of the less strongly coordinating ligand, PPh3, promotes vinyl-to allylrhodium isomerization en route to linear ketones. This method bypasses the 3-step sequence often used to convert aldehydes to ketones involving the addition of pre-metalated reagents to Weinreb or morpholine amides.
- Swyka, Robert A.,Shuler, William G.,Spinello, Brian J.,Zhang, Wandi,Lan, Chunling,Krische, Michael J.
-
supporting information
p. 6864 - 6868
(2019/05/10)
-
- Synthesis and biological properties of aryl methyl sulfones
-
A novel group of aryl methyl sulfones based on nonsteroidal anti-inflammatory compounds exhibiting a methyl sulfone instead of the acetic or propionic acid group was designed, synthesized and evaluated in vitro for inhibition against the human cyclooxygenase of COX-1 and COX-2 isoenzymes and in vivo for anti-inflammatory activity using the carrageenan induced rat paw edema model in rats. Also, in vitro chemosensitivity and in vivo analgesic and intestinal side effects were determined for defining the therapeutic and safety profile. Molecular modeling assisted the design of compounds and the interpretation of the experimental results. Biological assay results showed that methyl sulfone compounds 2 and 7 were the most potent COX inhibitors of this series and best than the corresponding carboxylic acids (methyl sulfone 2: IC50 COX-1 = 0.04 and COX-2 = 0.10 μM, and naproxen: IC50 COX-1 = 11.3 and COX-2 = 3.36 μM). Interestingly, the inhibitory activity of compound 2 represents a significant improvement compared to that of the parent carboxylic compound, naproxen. Further support to the results were gained by the docking studies which suggested the ability of compound 2 and 7 to bind into COX enzyme with low binding free energies. The improvement of the activity of some sulfones compared to the carboxylic analogues would be performed through a change of the binding mode or mechanism compared to the standard binding mode displayed by ibuprofen, as disclosed by molecular modeling studies. So, this study paves the way for further attention in investigating the participation of these new compounds in the pain inhibitory mechanisms. The most promising compounds 2 and 7 possess a therapeutical profile that enables their chemical scaffolds to be utilized for development of new NSAIDs.
- Navarro, Lorena,Rosell, Gloria,Sánchez, Silvia,Boixareu, Núria,Pors, Klaus,Pouplana, Ramon,Campanera, Josep M.,Pujol, M. Dolors
-
p. 4113 - 4126
(2018/07/06)
-
- A PROCESS FOR THE PREPARATION OF FIROCOXIB
-
The present invention provides an improved process for preparation of Firocoxib of Formula I. Further, the present invention relates to novel process for the preparation of crystalline polymorphic form B of Firocoxib of Formula I.
- -
-
Page/Page column 20; 21
(2018/07/05)
-
- Synthetic method of free-radical photoinitiator
-
The invention discloses a synthetic method of a free-radical photoinitiator. The synthetic method is characterized by comprising the following steps: (1) under the action of aluminium trichloride, methyl phenyl sulfide is adopted as a raw material and generates Friedel-Crafts acylation reaction with 2-chloroisobutyryl chloride to prepare an intermediate A with a structure shown in a formula (I); (2) under the action of alkaline, the intermediate A carries out ring-closure reaction to prepare an intermediate B with a structure shown in a formula (II); (3) the intermediate B and morpholine carryout ring-opening reaction to obtain a target product with a structure shown in a formula (III), namely the free-radical photoinitiator. The synthetic method disclosed by the invention has the beneficial effects that the photoinitiator is synthesized by the steps of adopting the 2-chloroisobutyryl chloride and methyl phenyl sulfide to carry out Friedel-Crafts acylation reaction, then carrying outcyclization and ring opening and the like, the obtained product contains fewer impurities, the yield is high, the process route is convenient in operation, and generates less three wastes (waste water, waste solid and waste air) so as to be more environment-friendly.
- -
-
Paragraph 0076; 0077; 0078; 0088
(2018/07/30)
-
- NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB
-
The present invention concerns a process for the preparation of firocoxib, i.e. 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)-furan-2-one, comprising steps (a)-(g), wherein the process provides for step (d) of the reaction of a new intermediate, i.e. 2-methyl-1-[4-(methylsulfanyl)phenyl]-1-oxopropan-2-yl (acetyloxy)acetate (compound VII) in the same organic solvent of step (a) in the presence of a catalyst and a phase transfer catalyst solution in the same organic solvent with hydrogen peroxide.
- -
-
Page/Page column 4; 7; 12; 13; 17
(2018/11/10)
-
- Firocoxib preparation method
-
The invention discloses a firocoxib preparation method and relates to the technical field of chemical synthesis, in particular to a novel method for synthesizing firocoxib. The novel method for synthesizing the firocoxib includes subjecting thioanisole serving as a raw material to acylation reaction, bromination reaction, oxidizing reaction, esterification reaction and cyclization reaction sequentially so as to obtain the firocoxib. Compared with a traditional technology, the novel method for synthesizing the firocoxib has the advantages that an aftertreatment process is simple without column chromatography separation, and the method is high in yield, low in cost and suitable for industrial production.
- -
-
Paragraph 0010; 0011
(2017/03/14)
-
- MICHAEL ADDITION REACTION PRODUCT AND ACTIVE ENERGY RAY-CURABLE COMPOSITION
-
The present invention provides a Michael addition reaction product between a specified compound having a group which functions as a Michael donor and a monomer or polymer having a group which functions as a Michael acceptor, a photoinitiator containing the Michael addition reaction product, and an active energy ray-curable composition containing the photoinitiator. The compound having a group functioning as a Michael donor used in the present invention is a phenyl ketone derivative and is characterized by having an amino group or a mercapto group as the group functioning as a Michael donor.
- -
-
Page/Page column 17
(2012/05/20)
-
- PROCESS FOR PREPARING AROMATIC THIOPHENYL KETONES
-
The invention provides a process for synthesizing aromatic thioether ketones comprising reacting an aromatic thioether with an acylating agent in the presence of heteropoly acids or heteropoly acid-containing solid supports or the salts of heteropoly acids.
- -
-
Page/Page column 20-21
(2008/06/13)
-
- An improved and practical synthesis of 5,5-dimethyl-3-(2-propoxy)-4-(4-methanesulfonylphenyl)-2-(5H)-furanone (DFP - A selective inhibitor of cyclooxygenase-2)
-
DFP, a highly selective and potent COX-2 inhibitor, has been synthesized by a modified approach. Three modifications of the existing method enabled us to prepare DFP in good quantity.
- Padakanti, Srinivas,Pal, Manojit,Yeleswarapu, Koteswar Rao
-
p. 7915 - 7920
(2007/10/03)
-
- (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES WITH OXYGEN LINK AS COX-2 INHIBITORS
-
The invention encompasses the novel compound of Formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising co
- -
-
-
- A highly active ytterbium(III) methide complex for truly catalytic Friedel-Crafts acylation reactions
-
The Friedel-Crafts acylation of anisole with acetic anhydride using ytterbium(III) tri[tris(nonafluorobutanesulfonyl)methide] was studied with respect to catalyst loading. A strong inhibitory effect due to the product became apparent from doping experiments and from examination of the kinetic data. This understanding allowed catalyst loadings to be reduced to as little as 0.1 mol% for effective acylation under a suitable temperature and pressure regime.
- Barrett, Anthony G. M.,Bouloc, Nathalie,Braddock, D. Christopher,Chadwick, David,Henderson, David A.
-
p. 1653 - 1656
(2007/10/03)
-
- Diaryl-2-(5H)-furanones as Cox-2 inhibitors
-
The invention encompasses the novel compound of Formula (I) as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula (I). The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula (I).
- -
-
-
- (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors
-
The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising comp
- -
-
-
- ALKYLATED STYRENES AS PRODRUGS TO COX-2 INHIBITORS
-
The invention encompasses the novel compound of formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of formula (I).
- -
-
-
- SAR in the alkoxy lactone series: The discovery of DFP, a potent and orally active COX-2 inhibitor
-
Extensive SAR has been established in the alkoxy lactone series and this has lead to the discovery of DFP (5,5-dimethyl-3-(2-propoxy)-4- methanesulfonylphenyl)-2(5H)-furanone), a potent COX-2 inhibitor exhibiting in vivo efficacy in all models studied.
- Leblanc,Roy,Boyce,Brideau,Chan,Charleson,Gordon,Grimm,Guay,Leger,Li,Riendeau,Visco,Wang,Webb,Xu,Prasit
-
p. 2207 - 2212
(2007/10/03)
-
- A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors
-
By inserting an oxygen link between the 3-fluorophenyl and the lactone ring of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methanesulfonylphenyl)-2(5H)-furanone 1 (DFU), analogs with enhanced in vitro COX-2 inhibitory potency as well as in vivo potency in models of inflammation were obtained.
- Li, Chun-Sing,Black, W. Cameron,Brideau, Christine,Chan, Chi Chung,Charleson, Stella,Cromlish, Wanda A.,Claveau, David,Yves Gauthier, Jacques,Gordon, Robert,Greig, Gillian,Grimm, Erich,Guay, Jocelyne,Lau, Cheuk K.,Riendeau, Denis,Therien, Michel,Visco, Denise M.,Wong, Elizabeth,Xu, Lijing,Prasit, Petpiboon
-
p. 3181 - 3186
(2007/10/03)
-
- (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
-
The invention encompasses the novel compound of Formula A that is useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula A.
- -
-
-
- 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to COX-2 inhibitors
-
The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
- -
-
-
- The Methyl Group as A Protecting Group for Arylthiols: A Mild and Efficient Method for the Conversion of Methyl Aryl Sulfides to Arylthiols
-
Methyl aryl sulfides are converted in a mild, "one-pot", three step procedure via Pummerer rearrangement of the corresponding sulfoxides, and without purification of intermediates, to provide arylthiols in excellent yields.
- Young, Robert Norman,Gauthier, Jacques Yves,Coombs, William
-
p. 1753 - 1756
(2007/10/02)
-